Carregant...
Regarding the Article by Rugo et al.
This letter to the editor highlights additional analyses to add to the recently reported study by Rugo et al., regarding abemaciclib treatment for HR+/HER2− breast cancer.
Guardat en:
| Publicat a: | Oncologist |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley & Sons, Inc.
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8265371/ https://ncbi.nlm.nih.gov/pubmed/33818868 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13781 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|